Abstract:Background: The development of osteoporosis is often accompanied by autophagy disturbance, which also caused new osteoblasts defects from bone marrow mesenchymal stem cells (BMSCs). However, the underlying molecular mechanisms are still not fully understood. Methyltransferase-like 14 (METTL14) is the main enzyme for N6-methyladenosine (m6A), the most prevalent internal modification in mammalian mRNAs, and it has been implicated in many bioprocesses. We aimed to explore the biological functions of autophagy mediated by METTL14 in osteoporosis and the possibility of METTL14 as an effective target for the treatment of osteoporosis.Methods: Calcein staining and microcomputed tomography (μ-CT) were used to analyze the bone formation. immunohistochemical (IHC) staining was used to detect the expression of METTL14 and beclin-1 in bone tissues. The quantitative real time PCR (qRT-PCR) and western blotting were used to analyze the mRNA and protein expressions. Alizarin red staining (ARS) and alkaline phosphatase (ALP) staining were used to explore the osteogenic differentiation of BMSCs. The production of autophagy was determined by transmission electron microscopy (TEM) and mRFP-GFP-LC3 adenoviral. Moreover, RNA binding protein immunoprecipitation (RIP)-qPCR was used to investigate the m6A modification of beclin-1 and the binding capability of beclin-1 and IGF2BPs.Findings: Herein, we demonstrate that the expression of METTL14 is downregulated during the development of osteoporosis both in human and mice. In vivo, METTL14+/- knockdown mice exhibits elevated bone loss and impaired autophagy similar to the ovariectomized (OVX) mice, while injecting METTL14 overexpressing adenovirus delays the process of osteoporosis.In vitro, forced expression of METTL14 significantly facilitates the osteogenic differentiation ability of BMSCs through regulating the activation of autophagy by enhancing the expression of beclin-1 dependent on the m6 A modification; the opposite is true under METTL14 silencing condition. Subsequently, m6A-binding proteins IGF2BP1/2/3 recognize m6A methylated beclin-1 mRNA and promotes its translation via mediating RNA stabilization.Interpretation: Our study reveals the METTL14-IGF2BPs-beclin-1 signaling axis in BMSCs osteogenic differentiation and highlights the critical roles of METTL14 mediated m 6 A modification in osteoporosis.Funding: This work was supported by grants from the National Natural Science Fund of China (81972117), Natural Science Foundation of Heilongjiang Province of China for excellent youth (JJ2020JQ0004), The First Affiliated Hospital of Harbin Medical University Excellent Young Talents Funding (HYD2020JQ0013), Special fund for clinical research of Wu Jieping Medical Foundation (320.6750.2020-04-50), and CAMS Innovation Fund for Medical Sciences (CIFMS, 2020-I2M-5-003).Declaration of Interest: The authors declare that they have no competing interests.Date AvailabilityEthical Approval: The experiments were performed under the guidance of the Experimental Animal Ethic Committee of the Harbin Medical University.

METTL3 Inhibits BMSC Apoptosis and Facilitates Osteonecrosis Repair Via an M6a-Igf2bp2-dependent Mechanism

Hypoxic Condition Induced H3K27me3 Modification of the LncRNA Tmem235 Promoter Thus Supporting Apoptosis of BMSCs

METTL3-m<SUP>6</SUP>A methylase regulates the osteogenic potential of bone marrow mesenchymal stem cells in osteoporotic rats via the Wnt signalling pathway

METTL3-mediated LINC00657 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells Via Mir-144-3p/bmpr1b Axis

Mettl3-mediated M(6)a RNA Methylation Regulates the Fate of Bone Marrow Mesenchymal Stem Cells and Osteoporosis

LINC00473-modified bone marrow mesenchymal stem cells incorporated thermosensitive PLGA hydrogel transplantation for steroid-induced osteonecrosis of femoral head: A detailed mechanistic study and validity evaluation

METTL3 Induces Bone Marrow Mesenchymal Stem Cells Osteogenic Differentiation and Migration Through Facilitating M1 Macrophage Differentiation.

M6a Methylation of Precursor-miR-320/RUNX2 Controls Osteogenic Potential of Bone Marrow-Derived Mesenchymal Stem Cells.

LncAABR07053481 inhibits bone marrow mesenchymal stem cell apoptosis and promotes repair following steroid-induced avascular necrosis

Mettl3 Regulates Osteogenic Differentiation And Alternative Splicing Of Vegfa In Bone Marrow Mesenchymal Stem Cells

UP-REGULATION OF ENDOGENOUS LEPTIN IMPROVES HUMAN MESENCHYMAL STEM CELL SURVIVAL ABILITY IN VITRO AND THIS CELLS PROTECT FATAL CARDIAL MYOCYTES FROM APOPTOSIS

METTL14 Regulates Autophagy and Osteogenic Differentiation of BMSCs Targeting Beclin-1 Via an M 6 A-IGF2BPs-Dependent Mechanism

Silencing MicroRNA-137-3p, which Targets RUNX2 and CXCL12 Prevents Steroid-induced Osteonecrosis of the Femoral Head by Facilitating Osteogenesis and Angiogenesis

METTL3-deficiency Suppresses Neural Apoptosis to Induce Protective Effects in Cerebral I/R Injury via Inhibiting RNA m6A Modifications: A Pre-clinical and Pilot Study

Epitranscriptomic Regulation of Osteoblast Function: Unveiling the Role of METTL3 and the m6A/YTHDF3/SOX4 Signaling Axis

METTL3 Mediates Osteoblast Apoptosis by Regulating Endoplasmic Reticulum Stress During LPS-induced Inflammation.

Bone marrow mesenchymal stem cell-derived exosomes promote osteoblast proliferation, migration and inhibit apoptosis by regulating KLF3-AS1/miR-338-3p

Downregulation of the LncRNA MEG3 Promotes Osteogenic Differentiation of BMSCs and Bone Repairing by Activating Wnt/-Catenin Signaling Pathway

Methyltransferase-like 3 modulates osteogenic differentiation of adipose-derived stem cells in osteoporotic rats

Long Noncoding RNA MEG3 Silencing Protects Against Hypoxia-Induced Pheochromocytoma-12 Cell Injury Through Inhibition of TIMP2 Promoter Methylation.

METTL14 Regulates Osteogenesis of Bone Marrow Mesenchymal Stem Cells via Inducing Autophagy Through m6A/IGF2BPs/Beclin-1 Signal Axis